1stOncology™: Cancer Intelligence Service – Page 14389 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

On May 6, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will be webcasting its corporate presentations at two upcoming investor conferences (Press release, Jazz Pharmaceuticals, MAY 6, 2019, View Source [SID1234535779]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 14, 2019 at 8:00 a.m. PDT / 4:00 p.m. IST. Dan Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update.
RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 9:00 a.m. EDT / 2:00 p.m. IST. Matt Young, executive vice president and chief financial officer, will provide an overview of the company and a business and financial update.
A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of each webcast will be available for at least one week following each presentation on the Investors section of the company’s website at www.jazzpharmaceuticals.com.

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

On May 6, 2019 VolitionRx Limited (NYSE American: VNRX) reported it will host a conference call on Thursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business update (Press release, VolitionRX, MAY 6, 2019, View Source [SID1234535778]).

Event: VolitionRx Limited First Quarter 2019 Earnings and Business Update Conference Call
Date: Thursday, May 9, 2019
Time: 8:30 a.m. Eastern time
U.S. & Canada Dial-in: 1-855-327-6837 (toll free)
U.K. Dial-in: 0 808-101-2791 (toll free)
Toll/International: 1-631-891-4304
Conference ID: 10006803

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition’s activities, including details of new and ongoing clinical trials, important events that have taken place in the first quarter of 2019, and milestones for the remainder of 2019 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition’s corporate website at View Source In addition, a telephone replay of the call will be available until May 23, 2019. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 10006803.

NuVasive To Present At The Bank of America Merrill Lynch Healthcare Conference 2019

On May 6, 2019 NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, reported that management will present at the Bank of America Merrill Lynch Healthcare Conference 2019 at the Encore Hotel in Las Vegas on Wednesday, May 15, 2019, at 1:40 p.m. PT/4:40 p.m. ET (Press release, NuVasive, MAY 6, 2019, View Source [SID1234535777]).

A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the live webcast.

QIAGEN Reports Results for First Quarter of 2019 and Announces Plans for New $100 Million Share Repurchase Program

On May 6, 2019 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported results of operations for the first quarter of 2019, meeting its outlook for net sales growth at constant exchange rates, or CER, and exceeding the outlook for adjusted earnings per share at CER while driving global expansion of its Sample to Insight portfolio of molecular testing solutions (Press release, Qiagen, MAY 6, 2019, View Source [SID1234535775]).

"Our performance for the first quarter of 2019 was in line with our outlook for solid sales growth and continued improvements in profitability. QIAGEN is reaffirming the full-year outlook set for this year," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "We have made significant progress in 2019 on advancing our portfolio of differentiated Sample to Insight solutions and are looking forward to delivering on its value."

"We are well positioned to achieve our goals for full-year sales growth, and to deliver faster growth particularly in the second half of 2019 given the success of our growth initiatives as well as the soon anticipated U.S. approval of the QIAstat-Dx system for multiplex syndromic testing. Our QuantiFERON latent TB test grew in line with the 2019 sales target range in the first quarter of 2019, and we announced additional automation options for this important contributor in the global fight against tuberculosis. We also expanded our portfolio of solutions for next-generation sequencing, which remains on track to achieve $190 million of sales in 2019 compared to $140 million in 2018, with the launch of new liquid biopsy and gene panels integrated with QIAGEN bioinformatics solutions. The launch of two new fully integrated molecular testing solutions – QIAstat-Dx and NeuMoDx for integrated molecular laboratory testing – are progressing well in Europe, are receiving a very positive acceptance and we are ready to capture share gains and growth opportunities in their very large target markets. Our teams are developing a broad range of tests to further expand the utility of these novel systems. In Precision Medicine, we are pleased by the breakthrough U.S. regulatory approval for a new therascreen companion diagnostic that tests for variants of the biomarker FGFR to help guide treatment decisions for patients with urothelial cancer. We are moving ahead with the transformation of QIAGEN and are continuing to execute on a strategy to maximize the value of this differentiated portfolio of molecular testing solutions along the continuum from Life Sciences research to Molecular Diagnostics."

Physicians’ Education Resource® Presents the 20th Annual International Lung Cancer Congress®

On May 6, 2019 Physicians’ Education Resource (PER), a worldwide leading resource for continuing medical education, reported that it will host the 20th Annual International Lung Cancer Congress from July 25 to 27 at the Huntington Regency Huntington Beach in California (Press release, Physicians’ Education Resource, MAY 6, 2019, View Source [SID1234535774]). The program will be chaired by Dr. David R. Gandara, professor of medicine in the division of hematology/oncology at the University of California (UC) at Davis School of Medicine and the director of the thoracic oncology program and senior adviser to the director at UC Davis Comprehensive Cancer Center, and Dr. Roy S. Herbst, Ensign professor of medicine (medical oncology), professor of pharmacology, chief of medical oncology and associate director for translational research at Yale Cancer Center, Yale School of Medicine.

"We are excited to celebrate 2 decades of educational excellence with this year’s upcoming International Lung Cancer Congress," said Phil Talamo, president of PER. "Now in its 20th year, the congress has become one of the most comprehensive and detailed educational lung cancer meetings in the world, with national and international faculty sharing perspectives on evolving data, discussing new patient management strategies, and reflecting on the evidence that drives the future treatment of lung cancer."

The 20th Annual International Lung Cancer Congress is a three-day program for surgical, medical and radiation oncologists interested in the treatment of patients with lung cancer. During this meeting, leading international and national experts will provide perspectives on how to incorporate the latest data on targeted agents, immunotherapy, surgery and radiation oncology in the clinic through a series of cutting-edge lectures, panel discussions, multidisciplinary tumor boards and interactive Q&A sessions. Attendees who participate will have the opportunity to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.